Cases and Conversations—Evolving Radiation Strategies in HER2-Positive Breast Cancer: Early-Stage Through Metastatic Disease

Activity Overview

This online, on-demand virtual symposium brings together a multidisciplinary panel of breast cancer experts to translate evolving HER2-directed systemic therapy and radiation science into practical strategies for real-world care. Through case-based presentations and expert panel discussions with integrated data summaries, faculty deliver actionable guidance on integrating radiation with ADC-based therapy across early-stage and metastatic settings, managing overlapping pulmonary and cardiac toxicities, using recent and emerging trial data to appropriately escalate or de-escalate radiation, and coordinating multidisciplinary management of brain metastases and oligoprogressive disease. This dynamic program is designed to equip radiation oncologists and the broader care team to confidently and safely integrate local and systemic therapy across the HER2-positive continuum.

This educational activity is an archive of the live symposium held on September 27, 2026.

Target Audience

This educational activity is directed toward radiation oncologists, surgical oncologists, medical oncologists, advanced practice providers, nurses, and other health care practitioners involved in the treatment and management of breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate the safety profile of concurrent and sequential radiation therapy with trastuzumab deruxtecan, including strategies to distinguish drug-related interstitial lung disease from radiation pneumonitis
• Develop a radiation treatment plan that accounts for the overlapping pulmonary and cardiac toxicity risks associated with ADC-based systemic therapy in patients with HER2-positive breast cancer
• Assess the implications of recent and emerging clinical trial data for the role of radiation therapy in early-stage and metastatic HER2-positive breast cancer
• Apply a multidisciplinary framework to integrate systemic and local therapy options for patients with HER2-positive breast cancer and brain metastases

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.

This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.

The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.